Predicting prostate-specific antigen recurrence established: Now, who will survive?

Journal of Clinical Oncology

Volumn 20, Issue 15, 2002, Pages 3188-3190

  D'Amico, Anthony V ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRACHYTHERAPY; CANCER SURVIVAL; DATA BASE; EDITORIAL; FOLLOW UP; HUMAN; MALE; PARAMETER; POSTOPERATIVE CARE; PREDICTION; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; TREATMENT OUTCOME;

EID: 0036682005     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.20.15.3188     Document Type: Editorial

References (32)

1. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer
2. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update
3. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium
4. Analysis of risk factors for progression in patients with pathologically organ confined prostate cancers after radical retropubic prostatectomy
5. PSA failure despite pathologic organ confined disease: The basis for an adjuvant therapy trial
6. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer
7. Artificial neural networks in the diagnosis and prognosis of prostate cancer: A pilot study
8. Early prostate-specific antigen relapse after radical retropubic prostatectomy: Prediction on the basis of preoperative and postoperative tumor characteristics
9. Identification of intermediate-risk prostate cancer patients treated with radiotherapy suitable for neoadjuvant hormone studies
10. A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate cancer
11. The results of radical radiation therapy for men with clinically localized prostate cancer: An ASTRO sponsored multi-institutional pooled analysis
12. Prostate specific antigen and radiation therapy for clinically localized prostate cancer
13. Interstitial iodine- 125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma
14. The biologic basis and clinical application of three-dimensional conformal external beam radiation therapy in carcinoma of the prostate
15. Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy
16. Genetically engineered neural networks for predicting prostate cancer progression after radical prostatectomy
17. Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases
18. Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy: Results from the Cancer of the Prostate Strategic Urologic Research Endeavor database
19. Four prognostic groups predicting long term survival from prostate cancer following radiotherapy alone in RTOG clinical trials
20. Analyzing predictive models following definitive radiotherapy for prostate cancer
21. The clinical utility of the percent of positive prostate biopsies in defining biochemical outcome following radical prostatectomy for patients with clinically localized prostate cancer
22. Predicting disease recurrence in intermediate and high-risk patients undergoing radical prostatectomy using percent positive biopsies: Results from CaPSURE
23. The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external beam radiation therapy for patients with clinically localized prostate cancer
24. International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy
25. Evaluating the yield of medical tests
26. A comparison of two preoperative nomograms predicting recurrence following radical prostatectomy
27. Natural history of progression after PSA elevation following radical prostatectomy
28. Recurrence patterns after radical retropubic prostatectomy: Clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen
29. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer
30. Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: Clinical observations
31. Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy
32. Overall survival after prostate-specific-antigen detected recurrence following conformal radiation therapy